Cue Biopharma Inc expected to post a loss of 15 cents a share - Earnings Preview

Cue Biopharma

09/05/2025 13:02

Cue Biopharma Inc CUE.OQ CUE.O is expected to show a fall in quarterly revenue when it reports  results on May 12 (estimated) for the period ending March 31 2025

The Boston Massachusetts-based  company is expected to report a 26.2% decrease in revenue to $1.268 million from $1.72 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Cue Biopharma Inc is for a loss of 15 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Cue Biopharma Inc is $3.00​, above​ its last closing price of $0.77. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.16
-0.13
Beat
16.7
Sep. 30 2024
-0.20
-0.19
-0.17
Beat
11.7
Jun. 30 2024
-0.28
-0.28
-0.20
Beat
29.6​
Mar. 31 2024
-0.28
-0.28
-0.25
Beat
11.3
​​Dec. 31 2023
-0.28
-0.28
-0.29
Missed
-4.3
Sep. 30 2023
-0.30
-0.34
-0.24
Beat
29.9​
Jun. 30 2023
-0.30
-0.30
-0.29
Beat
4.9
Mar. 31 2023
-0.32
-0.29
-0.29
Met
0

This summary was machine generated May 9 at 12:02 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)